These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 24305043

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [Abstract] [Full Text] [Related]

  • 24. Impact of new treatment options for hepatitis C virus infection in liver transplantation.
    Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M.
    World J Gastroenterol; 2015 Oct 14; 21(38):10760-75. PubMed ID: 26478668
    [Abstract] [Full Text] [Related]

  • 25. [Antiviral treatment of chronic hepatitis C].
    Berger A.
    Med Monatsschr Pharm; 2012 Feb 14; 35(2):55-60. PubMed ID: 22400430
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. New developments in HCV therapy.
    Kronenberger B, Zeuzem S.
    J Viral Hepat; 2012 Jan 14; 19 Suppl 1():48-51. PubMed ID: 22233414
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).
    Sheridan DA, Neely RD, Bassendine MF.
    Clin Res Hepatol Gastroenterol; 2013 Feb 14; 37(1):10-6. PubMed ID: 22959093
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Drug-drug interactions during antiviral therapy for chronic hepatitis C.
    Kiser JJ, Burton JR, Everson GT.
    Nat Rev Gastroenterol Hepatol; 2013 Oct 14; 10(10):596-606. PubMed ID: 23817323
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
    Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T.
    Ann Pharmacother; 2015 Jun 14; 49(6):674-87. PubMed ID: 25770114
    [Abstract] [Full Text] [Related]

  • 37. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
    Klein MB, Rollet KC, Hull M, Cooper C, Walmsley S, Conway B, Pick N, Canadian Co-infection Cohort Study (CTN222) Investigators.
    Antivir Ther; 2013 Jun 14; 18(5):717-21. PubMed ID: 23211632
    [Abstract] [Full Text] [Related]

  • 38. Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus.
    Piroth L.
    Clin Res Hepatol Gastroenterol; 2011 Dec 14; 35 Suppl 2():S75-83. PubMed ID: 22248699
    [Abstract] [Full Text] [Related]

  • 39. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML, Dieterich DT.
    Semin Liver Dis; 2011 Nov 14; 31(4):399-409. PubMed ID: 22189979
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.